Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEssentra Regulatory News (ESNT)

Share Price Information for Essentra (ESNT)

Share Price is delayed by 15 minutes
Get Live Data
82.60    0.70 (0.85%)
Bid:
82.10
Ask:
82.60
Spread: 0.50 (0.609%)
Market Cap: £234.14m
ESNT Live PriceLast checked at - London Stock Exchange

Intraday Essentra Share Chart

FY 2023 Pre-Close Trading Update

17 Jan 2024 07:00

RNS Number : 9101Z
Essentra plc
17 January 2024
 

ESSENTRA PLC

PRE-CLOSE TRADING UPDATE

A resilient Q4 performance, FY23 expectations unchanged

 

Essentra plc ("Essentra", the "Group", or the "Company"), a leading global provider of essential components and solutions, today provides a trading update for the thirteen weeks ended 31 December 2023 ("Q4").

The Group's FY23 expectations remain unchanged. The Group expects to deliver adjusted operating profit for the full year in line with previous guidance. The business continues to demonstrate operational and financial resilience, remaining well positioned to continue to progress towards its medium-term targets.

Trading update

In Q4, the Group saw a sequential improvement in performance compared to the previous quarter. Group revenue on a like-for-like1 ("LFL") and trading day adjusted basis declined -3.6% in Q4 2023, compared to the same period in the prior year, an improvement on the -7.1% decline reported in Q3 2023, as comparatives continued to ease after a strong H1 2022 performance.

EMEA saw an improvement in new order momentum in Q4, whilst continuing to experience market softening as previously guided, in line with changes to the macro-environment. The AMERS region saw trading stability quarter on quarter, and remains focused on the improvement in destocking trends within distributor end-market channels. The APAC business has continued to demonstrate a gradual recovery.

Through a combination of disciplined and proactive initiatives taken through 2023, including effective sales pricing offsetting inflation, Group adjusted operating margins remain strong. Central corporate costs, that were re-sized in H1 2023, continue to be well managed, and remain in line with previous guidance of approximately £13m.

The BMP TAPPI acquisition, completed on 26 October 2023 is performing in line with management expectations, early integration plans are on track.

Outlook

With a robust and differentiated business model, underpinned by its breadth of customers, end market categories and geographical diversification, Essentra is well positioned, and continues to demonstrate through-cycle financial resilience. The Group's balance sheet and cash generation remain strong, providing optionality for investment in organic growth initiatives and earnings enhancing M&A.

Through operational leverage, acquisition synergies and the compounding benefit of cost actions taken by management in 2023, the Group remains confident in delivering progress towards its medium-term targets.

 

Commenting on today's announcement, Scott Fawcett, Chief Executive Officer, said:

"I'm pleased with Essentra's performance in its first full year as a standalone components business. This year, we have been operationally successful whilst navigating the macro-economic backdrop, with the execution of M&A, the expansion of our footprint and right-sizing of our central cost base. We are on track to deliver adjusted operating profit in line with previously shared guidance, and continue to progress towards our medium-term targets".

Notice of results

Essentra will release its preliminary results for the twelve months ended 31 December 2023 on 19 March 2024. Further details regarding the Company's presentation to analysts and investors will be provided nearer the time.

 

1. The term "like-for-like" describes the performance of the continuing business on a comparable basis, adjusting for the impact of acquisitions, disposals and foreign exchange. 2023 LFL sales performance is adjusted for the acquisition of the Wixroyd Group ("Wixroyd") on 1 December 2022 and BMP s.r.l ("BMP TAPPI") on 26 October 2023.

 

 

 

Enquiries

Essentra plc

FTI Consulting

Jack Clarke, Chief Financial Officer

Richard Mountain

Claire Goodman, Investor Relations Manager

Emma Reid, Company Secretary

Ariadna Peretz

FTI_essentra@fticonsulting.com

Tel: +44 (0)1908 359100

Tel: +44 (0)20 3727 1340

 

Notes to Editors

About Essentra plc

Essentra plc is a FTSE 250 company and a leading global provider of essential components and solutions, focusing on the manufacture and distribution of plastic injection moulded, vinyl dip moulded and metal items.

Headquartered in the United Kingdom, Essentra's global network extends to 28 countries worldwide and includes over 3,000 employees, 13 manufacturing facilities, 24 distribution centres and 33 sales & service centres serving c.74,000 customers with a rapid supply of low cost but essential products for a variety of applications in industries such as equipment manufacturing, automotive, fabrication, electronics, medical and renewable energy.

For further information, please visit www.essentraplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFSTLIIRLIS
Date   Source Headline
7th Jul 20267:50 amRNSHolding(s) in Company
1st Jul 20263:20 pmRNSTransaction in Own Shares
1st Jul 20263:19 pmRNSTotal Voting Rights
24th Jun 20267:00 amRNSCompletion of the Boteco acquisition
16th Jun 20267:00 amRNSDirectorate change
10th Jun 20269:47 amRNSHolding(s) in Company
1st Jun 20267:00 amRNSTotal Voting Rights
29th May 20262:32 pmRNSTransaction in Own Shares
21st May 202610:55 amRNSResult of AGM
20th May 20267:00 amRNSAcquisition of Boteco Srl
20th May 20267:00 amRNS2026 AGM Trading Update
14th May 20265:15 pmRNSDirector/PDMR Shareholding
12th May 20267:03 amRNSTransaction in Own Shares
1st May 202612:17 pmRNSTotal Voting Rights
29th Apr 20268:12 amRNSTransaction in Own Shares
28th Apr 20263:25 pmRNSDirector/PDMR Shareholding
24th Apr 20263:30 pmRNSDirector/PDMR Shareholding
22nd Apr 20268:15 amRNSTransaction in Own Shares
21st Apr 20264:09 pmRNSDirector/PDMR Shareholding
17th Apr 20267:52 amRNSHolding(s) in Company
15th Apr 202610:06 amRNSDirector/PDMR Shareholding
15th Apr 20268:24 amRNSTransaction in Own Shares
15th Apr 20268:18 amRNSHolding(s) in Company
9th Apr 20268:24 amRNSDirector/PDMR Shareholding
7th Apr 20267:00 amRNSDirector/PDMR Shareholding
7th Apr 20267:00 amRNSHolding(s) in Company
1st Apr 20264:45 pmRNSDirector/PDMR Shareholding
1st Apr 20263:21 pmRNSDirector/PDMR Shareholding
1st Apr 20263:15 pmRNSTransaction in Own Shares
1st Apr 20263:08 pmRNSTotal Voting Rights
30th Mar 20262:00 pmRNSAnnual Financial Report
24th Mar 202610:05 amRNSTransaction in Own Shares
24th Mar 20268:17 amRNSHolding(s) in Company
19th Mar 20268:43 amRNSDirector/PDMR Shareholding
17th Mar 20261:41 pmRNSDirector/PDMR Shareholding
17th Mar 202610:30 amRNSDirectorate change
17th Mar 202610:28 amRNSDirector/PDMR Shareholding
17th Mar 20267:00 amRNSResults for the Full Year Ended 31 December 2025
17th Mar 20267:00 amRNSResults for the Full Year Ended 31 December 2025
16th Mar 20269:40 amRNSTransaction in Own Shares
16th Mar 20269:40 amRNSTransaction in Own Shares
13th Mar 202612:00 pmRNSCompany Secretary Change
9th Mar 20269:00 amRNSNotice of Full Year 2025 Results
9th Mar 20267:00 amRNSTransaction in Own Shares
5th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20267:00 amRNSTotal Voting Rights
26th Feb 20267:00 amRNSTransaction in Own Shares
24th Feb 20267:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.